Authors: Nemunaitis, J Khuri, F Ganly, I Arseneau, J Posner, M Vokes, E Kuhn, J McCarty, T Landers, S Blackburn, A Romel, L Randlev, B Kaye, S Kirn, D

Citation: J. Nemunaitis et al., Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer, J CL ONCOL, 19(2), 2001, pp. 289-298

Authors: Clark, ME Landers, S Linde, R Sperber, J

Citation: Me. Clark et al., The GLBT Health Access Project: A state-funded effort to improve access tocare, AM J PUB HE, 91(6), 2001, pp. 895-896

Authors: DeMaria, A Kunches, L Mayer, K Cohen, C Epstein, P Werner, B Day, J DeCristofaro, J Landers, S Tang, Y Coady, W

Citation: A. Demaria et al., Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gp160 vaccine among adults with advanced HIV infection, J HUMAN VIR, 3(4), 2000, pp. 182-192

Authors: Nemunaitis, J Ganly, I Khuri, F Arseneau, J Kuhn, J McCarty, T Landers, S Maples, P Romel, L Randlev, B Reid, T Kaye, S Kirn, D

Citation: J. Nemunaitis et al., Selective replication and oncolysis in p53 mutant tumors with ONYX-015, anE1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial, CANCER RES, 60(22), 2000, pp. 6359-6366